Efficacy and safety of lobeglitazone added to metformin and sitagliptin combination therapy in patients with type 2 diabetes: A 52‐week, multicentre, randomized, placebo‐controlled, phase III clinical trial

Ähnliche Einträge

• A multicentre, double‐blind, placebo‐controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add‐on therapy in type 2 diabetic patients treated with metformin and dapagliflozin
  von: Soo Lim, et al.
  Veröffentlicht: (2024)
• Long‐term efficacy and safety of enavogliflozin in Korean people with type 2 diabetes: A 52‐week extension of a Phase 3 randomized controlled trial
  von: Soo Heon Kwak, et al.
  Veröffentlicht: (2024)
• EffiCacy and safety of ANagliptin when added to iNsulin and metformin therapy in patients with uncontrolled type 2 diAbetes ; randomized, placebo‐controlled, double‐blind, multicentre trial ( CANNA study)
  von: Ji Eun Jun, et al.
  Veröffentlicht: (2025)
• IRASNet: Improved Feature-Level Clutter Reduction for Domain Generalized SAR-ATR
  von: Jang, Oh-Tae, et al.
  Veröffentlicht: (2024)
• Efficacy and safety of adding a fourth oral antidiabetic drug versus metformin dose escalation in patients with type 2 diabetes inadequately controlled on triple oral combination therapy ( EFFORT ): A 24‐week, randomized, open‐label, multicenter trial
  von: So Ra Kim, et al.
  Veröffentlicht: (2026)